<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; 3SBio Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/3sbio-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Signs Deal With Japan-Based Takeda Pharmaceutical Company</title>
		<link>http://www.stockbloghub.com/2010/04/06/amag-amag-pharmaceuticals-signs-deal-with-japan-based-takeda-pharmaceutical-company/32916</link>
		<comments>http://www.stockbloghub.com/2010/04/06/amag-amag-pharmaceuticals-signs-deal-with-japan-based-takeda-pharmaceutical-company/32916#comments</comments>
		<pubDate>Tue, 06 Apr 2010 20:46:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3SBio Inc]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[IDA]]></category>
		<category><![CDATA[IdaCorp]]></category>
		<category><![CDATA[SSRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32916</guid>
		<description><![CDATA[Recently, AMAG Pharmaceuticals Inc. (AMAG) and Japan-based Takeda Pharmaceutical Co. Ltd. entered into a license, development and commercialization deal related to AMAG’s Feraheme (ferumoxytol) injection for intravenous (IV) use across all potential indications for the drug. Feraheme is an intravenous iron-replacement therapy for fighting anemia in patients with chronic kidney disease (CKD). The drug can be used by patients irrespective of dialysis. The deal, potentially worth $280 million, will grant Takeda rights to sell its anemia drug in some overseas markets. Specifically, the deal provides Takeda the rights to market Feraheme in Europe, the Commonwealth of Independent States, Canada, Turkey, and the Asia-Pacific region apart from China, Japan, and Taiwan. Under the terms of the agreement, AMAG will receive an upfront payment of $60 million. Furthermore, the Massachusetts-based company will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/06/amag-amag-pharmaceuticals-signs-deal-with-japan-based-takeda-pharmaceutical-company/32916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Reports Narrower Fourth Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/03/03/amag-amag-pharmaceuticals-reports-narrower-fourth-quarter-loss/29463</link>
		<comments>http://www.stockbloghub.com/2010/03/03/amag-amag-pharmaceuticals-reports-narrower-fourth-quarter-loss/29463#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:47:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3SBio Inc]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[SSRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29463</guid>
		<description><![CDATA[AMAG Pharmaceuticals Inc. (AMAG) reported a fourth-quarter fiscal 2009 net loss of $18.4 million, or $1.07 per share, which was lower than the year-ago loss of $21.8 million, or $1.28. The Zacks Consensus Estimate for the reported quarter was a loss of $1.08. The lower loss in the quarter was attributable to higher revenues following the approval and subsequent launch of the Feraheme injection. The higher revenue in the quarter more than offset the higher operating costs and expenses in the quarter attributable to increased selling, general and administrative expenses incurred for the commercialization of Feraheme. Revenue for the reported quarter came in at $13.1 million as opposed to $0.6 million in the year-ago period. Net product revenues of Feraheme stood at $12.8 million in the reported quarter Incorporatedluding $1.3 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/amag-amag-pharmaceuticals-reports-narrower-fourth-quarter-loss/29463/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMAG) AMAG Pharmaceuticals Guides on Feraheme</title>
		<link>http://www.stockbloghub.com/2010/01/12/amag-amag-pharmaceuticals-guides-on-feraheme/24690</link>
		<comments>http://www.stockbloghub.com/2010/01/12/amag-amag-pharmaceuticals-guides-on-feraheme/24690#comments</comments>
		<pubDate>Tue, 12 Jan 2010 23:55:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[3SBio Inc]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[SSRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24690</guid>
		<description><![CDATA[Recently, AMAG Pharmaceuticals Inc. (AMAG) stated that it expects net revenues between $12 and $13 million from its lead anti-anemia injectable product Feraheme for the fourth quarter of fiscal 2009 (ended December 31). AMAG had launched the Feraheme (ferumoxytol) injection in the United States on July 13, 2009. It is an intravenous iron replacement therapy to fight anemia in patients with chronic kidney disease (CKD). The drug can be used by patients even if they are undergoing dialysis. The company further stated that Feraheme has been purchased by more than 1,000 customers to date, approximately 60% of whom have bought the drug on a repeat basis. Management believes that approximately 60% of the demand for Feraheme since its launch has come from patients not undergoing dialysis. AMAG believes that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/12/amag-amag-pharmaceuticals-guides-on-feraheme/24690/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

